-

11:57:59 PM

KURA Stock News

KURA - Kura Oncology Inc

05/26/22 7:30 AM

Nasdaq : KURA

conferences

Kura Oncology to Participate in Three Upcoming Investor Conferences

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer,

RHEA-AI

neutral

05/04/22 4:05 PM

Nasdaq : KURA

earnings

Kura Oncology Reports First Quarter 2022 Financial Results

– Enrollment completed in Phase 1b expansion cohorts for ziftomenib; topline data expected in third quarter, full data presentation in fourth quarter – – Enrollment in PIK3CA-dependent cohort in KURRENT-HN trial of tipifarnib plus alpelisib continues; first patient in HRAS overexpression cohort

RHEA-AI

neutral

04/27/22 7:30 AM

Nasdaq : KURA

conferencesearnings

Kura Oncology to Report First Quarter 2022 Financial Results

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2022 financial results after the

RHEA-AI

neutral

04/08/22 1:00 PM

Nasdaq : KURA

clinical trial

Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer

– Late-breaking presentation at AACR demonstrates potential to significantly delay onset of drug resistance to EGFR-targeted therapies through combination with a farnesyl transferase inhibitor – – Company to initiate clinical trial of tipifarnib in combination with osimertinib in NSCLC in the third

RHEA-AI

neutral

03/08/22 5:30 PM

Nasdaq : KURA

Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Meeting

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the

RHEA-AI

neutral

02/28/22 7:30 AM

Nasdaq : KURA

conferences

Kura Oncology to Participate in Two Upcoming Investor Conferences

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer,

RHEA-AI

neutral

02/24/22 4:03 PM

Nasdaq : KURA

earnings

Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results

– Patient enrollment continues in KOMET-001 Phase 1b study of ziftomenib (KO-539) in AML – – Multiple milestones and data readouts from KOMET-001 expected in 2022 – – First patients dosed in Phase 1/2 study of tipifarnib plus alpelisib in HNSCC – – Abstract supporting next-generation FTI program

RHEA-AI

neutral

02/17/22 7:30 AM

Nasdaq : KURA

conferencesearnings

Kura Oncology to Report Fourth Quarter and Full Year 2021 Financial Results

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2021 financial

RHEA-AI

neutral

02/10/22 7:30 AM

Nasdaq : KURA

conferences

Kura Oncology to Participate in SVB Leerink Global Healthcare Conference

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the 11 th Annual SVB Leerink Global Healthcare

RHEA-AI

neutral

02/01/22 4:01 PM

Nasdaq : KURA

management

Kura Oncology Expands Leadership Team with Key Promotions

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today

RHEA-AI

very positive

1 2 3 4 5 6 7 Next

KURA Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.kuraoncology.com
CeoTroy Wilson
Security nameKura Oncology Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees89
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address12730 High Bluff Drive, Suite 400
StateCalifornia
CitySan Diego
Zip92130
CountryUS
Phone18585008800

About Kura Oncology Inc

Tipifarnib, is a potent, selective and orally bioavailable inhibitor of farnesyl transferase in-licensed from Janssen. Previously, tipifarnib was studied in more than 5,000 cancer patients and showed compelling and durable anti-cancer activity in certain patient subsets; however, no molecular mechanism of action had been determined that could explain its clinical activity across a range of solid tumor and hematologic indications. Leveraging advances in next generation sequencing as well as emerging information about cancer genetics and tumor biology, the Company is seeking to identify those patients most likely to benefit from tipifarnib. In addition to Breakthrough Therapy Designation, tipifarnib has been granted Fast Track designation by the FDA for the treatment of patients with HRAS mutant HNSCC. In addition to HNSCC, tipifarnib has demonstrated encouraging clinical activity in a number of additional genetically defined tumor types. Kura has received multiple issued patents for tipifarnib, providing patent exclusivity in the U.S. and foreign countries. About Kura Oncology